Status:
COMPLETED
SHOX2_PTGER4 DNA Methlyation in Lung Cancer
Lead Sponsor:
University Hospital, Essen
Conditions:
Lungcancer
Eligibility:
All Genders
18-95 years
Brief Summary
Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis. In this study a control group consisting of COPD patients with a CT-scan of the chest no ...
Detailed Description
Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis. In this study a control group consisting of COPD patients with a CT-scan of the chest no ...
Eligibility Criteria
Inclusion
- suspicious finding for lung cancer on CT-scan
Exclusion
- history significant for former malignant diseases
Key Trial Info
Start Date :
May 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04321499
Start Date
May 1 2016
End Date
March 1 2017
Last Update
March 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruhrlandklinik, Department of Interventional Pneumology
Essen, North Rhine-Westphalia, Germany, 45239